On March 28, 2023 (the Effective Date), AbbVie Inc. entered into an amended and restated revolving credit agreement (Second Amended and Restated Revolving Credit Agreement) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the Agent), providing for the amendment and restatement, effective as of the Effective Date, of that certain amended and restated revolving credit agreement, dated as of August 27, 2019, among AbbVie, as borrower, the lenders and other parties party thereto and the Agent. The Second Amended and Restated Revolving Credit Agreement: (i) increases the unsecured revolving credit facility commitments from $4.0 billion to $5.0 billion and (ii) extends the maturity date of the facility from August 27, 2024 to March 28, 2028.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
164.7 USD | +0.25% | -1.71% | +6.25% |
Apr. 18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... | |
Apr. 18 | AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.25% | 291B | |
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.81% | 144B | |
-8.80% | 142B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Inc. Enter into an Amended and Restated Revolving Credit Agreement with JPMorgan Chase Bank, N.A